<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554216</url>
  </required_header>
  <id_info>
    <org_study_id>OB-302</org_study_id>
    <nct_id>NCT00554216</nct_id>
  </id_info>
  <brief_title>Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI ≥ 35</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521
      compared to placebo in treatment of obesity in an adult population with BMI ≥ 35.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Weight Loss From Baseline to Week 56</measure>
    <time_frame>baseline to 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 5% Weight Loss at Week 56</measure>
    <time_frame>baseline to 56 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1267</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>VI-0521 Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Top</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>3.75 mg phentermine/23 mg topiramate</description>
    <arm_group_label>VI-0521 Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>15 mg phentermine/92 mg topiramate</description>
    <arm_group_label>VI-0521 Top</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matched phentermine/topiramate</intervention_name>
    <description>Placebo matched phentermine/topiramate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥ 35 kg/m2

          -  Informed consent

          -  70 years of age or less

          -  Triglyceride level ≤ 200 mg/dL with treatment of 0 or 1 medications

          -  Blood pressure of ≤ 140/90 mmHg with treatment of 0-2 medications for hypertension

          -  Fasting blood glucose level of ≤ 110 mg/dL

        Exclusion Criteria:

          -  Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months

          -  Clinically significant renal, hepatic or psychiatric disease

          -  Unstable thyroid disease or replacement therapy

          -  Nephrolithiasis

          -  Obesity of known genetic or endocrine origin

          -  Participation in a formal weight loss program or lifestyle intervention

          -  History of glaucoma or intraocular pressure

          -  Pregnancy or breastfeeding

          -  Alcohol abuse

          -  Smoking cessation within previous 3 months or plans to quit smoking during study

          -  Eating disorders

          -  Cholelithiasis within past 6 months

          -  Excluded medications

          -  Type 2 diabetes

          -  Previous bariatric surgery

          -  History of bipolar disorder or psychosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Peterson</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kishore Gadde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research</name>
      <address>
        <city>Ridgefield</city>
        <state>Connecticut</state>
        <zip>06877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2007</study_first_submitted>
  <study_first_submitted_qc>November 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <results_first_submitted>July 31, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 6, 2012</results_first_posted>
  <disposition_first_submitted>November 30, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 2, 2009</disposition_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity, morbid obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject recruitment occurred at investigative sites in the US between November 2007 through May 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>VI-0521 Low</title>
          <description>PHEN/TPM 3.75 mg/23 mg</description>
        </group>
        <group group_id="P3">
          <title>VI-0521 Top</title>
          <description>PHEN/TPM 15 mg/92 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="514"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="512"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="340"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="172"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Restricted med</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>VI-0521 Low</title>
          <description>PHEN/TPM 3.75/23</description>
        </group>
        <group group_id="B3">
          <title>VI-0521 Top</title>
          <description>PHEN/TPM 15/92</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="514"/>
            <count group_id="B2" value="241"/>
            <count group_id="B3" value="512"/>
            <count group_id="B4" value="1267"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="11.76"/>
                    <measurement group_id="B2" value="43.0" spread="10.96"/>
                    <measurement group_id="B3" value="42.0" spread="12.21"/>
                    <measurement group_id="B4" value="42.6" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="425"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="424"/>
                    <measurement group_id="B4" value="1050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="514"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="512"/>
                    <measurement group_id="B4" value="1267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Weight Loss From Baseline to Week 56</title>
        <time_frame>baseline to 56 weeks</time_frame>
        <population>intent-to-treat last-observation-carried-forward (ITT-LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>VI-0521 Low</title>
            <description>PHEN/TPM 3.75 mg/23 mg</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top</title>
            <description>PHEN/TPM 15 mg/92 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Loss From Baseline to Week 56</title>
          <population>intent-to-treat last-observation-carried-forward (ITT-LOCF)</population>
          <units>percent weight loss</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="498"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.395"/>
                    <measurement group_id="O2" value="5.10" spread="0.538"/>
                    <measurement group_id="O3" value="10.92" spread="0.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With at least 250 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.476</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.43</ci_lower_limit>
            <ci_upper_limit>10.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With at least 250 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.596</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.38</ci_lower_limit>
            <ci_upper_limit>4.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With at least 250 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.596</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.65</ci_lower_limit>
            <ci_upper_limit>6.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 5% Weight Loss at Week 56</title>
        <time_frame>baseline to 56 weeks</time_frame>
        <population>intent-to-treat last-observation-carried-forward (ITT-LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>VI-0521 Low</title>
            <description>PHEN/TPM 3.75 mg/23 mg</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top</title>
            <description>PHEN/TPM 15 mg/92 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 5% Weight Loss at Week 56</title>
          <population>intent-to-treat last-observation-carried-forward (ITT-LOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="498"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="44.9"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With at least 250 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.463</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.13</ci_lower_limit>
            <ci_upper_limit>12.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With at least 250 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.706</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.80</ci_lower_limit>
            <ci_upper_limit>5.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With at least 250 subjects in each of the 3 arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.394</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from when written informed consent was provided through 28 days after the last dose of investigational product.</time_frame>
      <desc>Only subjects who received at least one dose of study drug were included in the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>VI-0521 Low</title>
          <description>PHEN/TPM 3.75/23</description>
        </group>
        <group group_id="E3">
          <title>VI-0521 Top</title>
          <description>PHEN/TPM 15/92</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>pancreatitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>myeloid leukemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Proplapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="374" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="432" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution &amp; PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wesley W. Day PhD</name_or_title>
      <organization>Vivus, Inc.</organization>
      <phone>650-934-5200</phone>
      <email>day@vivus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

